Price movement over the last 24 hours
Abbott Laboratories vs Invesco DB Commodity Index Tracking Fund — how do they compare? Abbott Laboratories trades at $95.17 (market cap $166.94B), while Invesco DB Commodity Index Tracking Fund trades at $27.75. The key difference: Abbott Laboratories pays a 2.63% dividend while Invesco DB Commodity Index Tracking Fund pays none, and Invesco DB Commodity Index Tracking Fund is trading nearer its 52-week high, Abbott Laboratories nearer its low. Which is the better fit depends on your goals.
| ABT | DBC | |
|---|---|---|
Market Cap | $166.94B | — |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $136.62 | $31.69 |
52-Week Low | $82.57 | $21.62 |
Enterprise Value | $193.69B | — |
Dividend Yield | 2.63% | — |
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.63, up 0.25% on the day, with a bullish technical signal from moving averages and strong analyst support. The stock shows solid fundamentals with a P/E of 26.79 and net income margin of 13.91%, though recent earnings have been mixed. Recent news highlights regulatory approvals for new medical devices, supporting growth prospects.
The outlook remains positive with a consensus price target of $122.55, implying significant upside. Key risks include competitive pressures and macroeconomic headwinds, but strong institutional backing and consistent dividend payments provide stability for long-term investors.
DBC trades at $27.00, up 1.62% with a bullish technical signal supported by strong momentum indicators. The commodity ETF shows resilience amid inflation concerns, recently hitting 52-week highs according to Zacks Investment Research (April 29, 2026). Current price action consolidates near key support/resistance levels with mixed moving average signals suggesting near-term consolidation potential.
Outlook remains positive as commodities gain traction for inflation hedging, though the ETF faces headwinds from commodity price volatility and geopolitical risks. The equal-weight portfolio strategy showing strong 2026 performance provides additional tailwinds for diversified commodity exposure.
Trailing returns across standard periods
Latest headlines on both assets
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →DBC is a diversified commodity ETF that tracks the DBIQ Optimum Yield Diversified Commodity Index. It invests in futures contracts for 14 heavily traded commodities, including crude oil, gold, and corn, while optimizing for yield and roll costs.
Read more on DBC →